This text is a result of machine translation.
There were 89 financing cases in the primary market this week, with an increase of 11.25% month on month. Zhongxin wafer obtained a strategic investment of 1.1 billion yuan
China's First Oral COVID-19 Antiviral Medicine in Dispute
An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.
Aug 08, 2022 09:00 AM
Zelensky called on the international community to provide funds for Ukraine's reconstruction, which is expected to cost $500 billion
913 companies have been investigated by public funds since the second quarter, and the six top flow fund managers focus on the leaders of subdivided industries
Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab
The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.
Sep 20, 2022 03:35 PM
Thinking of ASEAN as a single market is the biggest miscalculation for Chinese companies
Updated 4 hours ago
You're Invited: China's Innovation, Up Close
Feb 10, 2026 04:21 PM
CES 2026 in Numbers | From Shenzhen to Las Vegas: Huaqiangbei’s Year-End Report
Jan 15, 2026 09:42 PM